Delivering a Next Generation Platform for Antibody Drug Discovery
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses.
In June 2018, Deerfield Management and Ablexis signed a definitive agreement under which Deerfield Management will acquire Ablexis.
Year Invested: 2009